The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer

Kunovský, Lumír; Tesaříková, Pavla; Kala, Zdeněk; Kroupa, Radek; Kysela, Petr; Dolina, Jiří; Trna, Jan

doi:10.1155/2018/5389820

Cited by 51 publications

(49 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, patients who are negative for Lewis antigen a or b (approximately 10% of patients with PDAC) are unable to synthesize CA 19-9 even in advanced stages of the disease. Although measurement of serum CA 19-9 levels is useful in patients with known pancreatic cancer, the application of this biomarker as a screening tool revealed disappointing results and is not recommended as a screening marker for PDAC [46,47,51]. Our working group recently identified a metabolite-based biomarker signature, which distinguishes PDAC from CP with much greater accuracy than CA 19-9 alone [52].…”

Section: Opportunities Of Metabolic Profiles To Develop Targeted Thermentioning

confidence: 99%

Current Strategies and Future Perspectives for Precision Medicine in Pancreatic Cancer

Regel

Mayerle

Mahajan

2020

Cancers

View full text Add to dashboard Cite

Current standard-of-care for patients with pancreatic ductal adenocarcinoma (PDAC) focusses on chemotherapeutic regimens and pancreatic cancer surgery. However, limited treatment options, late diagnosis in advanced tumor stages and the aggressive behavior of PDAC contribute to the high mortality of the disease. Consequently, there is an urgent need of precision medicine for pancreatic cancer patients. All over the world, numerous initiatives started in recent years to translate novel scientific discoveries into prospective clinical trials. One major approach pursues the stratification of PDAC patients according the tumor transcriptome to predict treatment response. Other strategies concentrate on genomic alterations and the identification of individualized targeted therapies. Further experimental studies are ongoing to detect novel biomarkers for cancer diagnosis, subtyping, treatment response prediction or clinical outcome. However, the challenge remains to transfer the knowledge into clinical practice. In this review, we summarize current literature and knowledge and highlight novel concepts of basic and clinical research uncovering suitable biomarkers and targeted therapies. Thus, we provide an overview of preclinical and clinical efforts of precision medicine in pancreatic cancer.

show abstract

Section: Opportunities Of Metabolic Profiles To Develop Targeted Thermentioning

confidence: 99%

Current Strategies and Future Perspectives for Precision Medicine in Pancreatic Cancer

Regel

Mayerle

Mahajan

2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Most of the other potential protein-based biomarkers for early PDAC detection, including cell migration-inducing hyaluronan binding protein (CEMIP), C4b-binding protein α-chain (C4BPA), insulin-like growth factor-binding protein 2 (IGFBP2), insulin-like growth factor-binding protein 3 (IGFBP3), interleukin-1β (IL-1β), interleukin-8 (IL-8), interleukin-10 (IL-10), vascular endothelial growth factor (VEGF), and macrophage inhibitory cytokine-1 (MIC-1) [ 30 ], could theoretically be targeted by aptamers, too. Due to a lack of large prospective clinical trials, aptamer-based biosensors directed against potential tumor biomarkers are currently only established for VEGF, a key player of angiogenesis and metastasis formation in various cancer entities [ 31 ].…”

Section: Introductionmentioning

confidence: 99%

Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma

Maier

et al. 2020

Radiat Oncol

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is an extremely challenging disease with a high mortality rate and a short overall survival time. The poor prognosis can be explained by aggressive tumor growth, late diagnosis, and therapy resistance. Consistent efforts have been made focusing on early tumor detection and novel drug development. Various strategies aim at increasing target specificity or local enrichment of chemotherapeutics as well as imaging agents in tumor tissue. Aptamers have the potential to provide early detection and permit anti-cancer therapy with significantly reduced side effects. These molecules are in-vitro selected single-stranded oligonucleotides that form stable threedimensional structures. They are capable of binding to a variety of molecular targets with high affinity and specificity. Several properties such as high binding affinity, the in vitro chemical process of selection, a variety of chemical modifications of molecular platforms for diverse function, non-immunoreactivity, modification of bioavailability, and manipulation of pharmacokinetics make aptamers attractive targets compared to conventional cell-specific ligands. To explore the potential of aptamers for early diagnosis and targeted therapy of PDAC-as single agents and in combination with radiotherapy-we summarize the generation process of aptamers and their application as biosensors, biomarker detection tools, targeted imaging tracers, and drug-delivery carriers. We are furthermore discussing the current implementation aptamers in clinical trials, their limitations and possible future utilization.

show abstract

“…Hence, there is an urgent need for the identification of some other parameter or method which could distinguish between the two types of head masses confirmatively. There are also studies looking into the proteome profile of pancreatic cancer and pancreatitis but with not much success [ 8 , 9 ]. Analysis of transcriptome has also been used to distinguish benign and malignant lesions in other cancers [ 10 , 11 ], but such studies directly addressing issues with benign and malignant pancreatic head masses are lacking.…”

Section: Introductionmentioning

confidence: 99%

Transcriptome analysis identifies putative multi-gene signature distinguishing benign and malignant pancreatic head mass

Chhatriya¹,

Mukherjee²,

Ray³

et al. 2020

J Transl Med

View full text Add to dashboard Cite

Background Most often, the patients with pancreatic diseases are presented with a mass in pancreatic head region and existing methods of diagnosis fail to confirm whether the head mass is malignant or benign. As subsequent management of the disease hugely depends on the correct diagnosis, we wanted to explore possible biomarkers which could distinguish benign and malignant pancreatic head masses. Methods In order to address that gap, we performed a case–control study to identify genome-wide differentially expressed coding and noncoding genes between pancreatic tissues collected from benign and malignant head masses. These genes were next shortlisted using stringent criteria followed by selection of top malignancy specific genes. They subsequently got validated by quantitative RT-PCR and also in other patient cohorts. Survival analysis and ROC analysis were also performed. Results We identified 55 coding and 13 noncoding genes specific for malignant pancreatic head masses. Further shortlisting and validation, however, resulted in 5 coding genes as part of malignancy specific multi-gene signature, which was validated in three independent patient cohorts of 145 normal and 153 PDAC patients. We also found that overexpression of these genes resulted in survival disadvantage in the patients and ROC analysis identified that combination of 5 coding genes had the AUROC of 0.94, making them potential biomarker. Conclusions Our study identified a multi-gene signature comprising of 5 coding genes (CDCA7, DLGAP5, FOXM1, TPX2 and OSBPL3) to distinguish malignant head masses from benign ones.

show abstract

The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer

Cited by 51 publications

References 93 publications

Current Strategies and Future Perspectives for Precision Medicine in Pancreatic Cancer

Current Strategies and Future Perspectives for Precision Medicine in Pancreatic Cancer

Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma

Transcriptome analysis identifies putative multi-gene signature distinguishing benign and malignant pancreatic head mass

Contact Info

Product

Resources

About